> ## Content Index
> Fetch the complete content index at: https://financeherald.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bayer's First-Ever Factor XIa Drug Rebuilds a Shrunken Blockbuster Bet
- URL: https://financeherald.com/bayers-first-ever-factor-xia-drug-rebuilds-a-shrunken-blockbuster-bet/
- Published: 2026-11-12T15:02:44.000Z
- Updated: 2026-11-12T15:02:44.000Z
- Description: The FDA cleared Bayer's Sunharbo as the first factor XIa inhibitor, but peak sales hopes sit above €1 billion, far below the original €5 billion thesis, with a $9,100 annual list price and a BMS/J&J rival closing in.
- Author: Finance Herald Staff
- Tags: Health & Pharma, News

### A rebuilt floor, not a windfall

Bayer has cleared a regulatory bar no drugmaker had reached before, but the celebration is quieter than the science deserves. The FDA on November 9 [approved](https://www.bayer.com/en-us/united-states/news-and-stories/2026/asundexian-fda?ref=financeherald.com) Sunharbo, making asundexian the first factor XIa inhibitor ever cleared in the United States, indicated alongside antiplatelet therapy to reduce stroke risk in adults after a recent non-cardioembolic ischemic stroke or high-risk TIA. The program carried Fast Track and Priority Review designations, and the approval went to Bayer HealthCare Pharmaceuticals.

What the approval does not restore is the scale Bayer once imagined for this molecule. Before 2023, the company hoped asundexian could generate peak annual sales above €5 billion, a figure built on its use in atrial fibrillation. That hope died when Bayer halted the phase 3 OCEANIC-AF trial early for lack of efficacy against Eliquis, rendering the original sales ambition [obsolete](https://www.marketscreener.com/news/bayer-hesitates-to-raise-sales-forecast-despite-asundexian-breakthrough-ce7e5ad9dc8ef122?ref=financeherald.com). The company now forecasts [peak](https://www.tradingview.com/news/tradingview:683b476e24575:0-key-facts-fda-approves-sunharbo-peak-sales-forecast-above-1bn/?ref=financeherald.com) sales above €1 billion, which clears the blockbuster threshold but sits far below the number analysts once modeled. The U.S. and European market is estimated at about €2 billion, and shares rose 1.3% to 1.5% in early trading, their highest level since May 2023.

### Why the smaller prize still matters

The rebuilt forecast lands at a vulnerable moment. Bayer's pharmaceutical division is contending with the loss of patent protection for Xarelto, one of its highest-revenue blood thinners, so any new anticoagulant franchise carries outsized strategic weight. Some analysts think asundexian could eventually reach around €3 billion in annual sales, per estimates cited by Reuters and [pharmaphorum](https://pharmaphorum.com/news/bayer-gets-first-approval-stroke-drug-asundexian?ref=financeherald.com), though that would require the drug to outgrow the addressable market most analysts currently size. Bayer will market the medicine directly in the U.S., a decision that keeps the economics in-house.

The clinical evidence supports a genuine but measured case. In the OCEANIC-STROKE phase 3 study, 12,327 adults were randomized to Sunharbo or placebo within 72 hours of symptom onset, and the 50 mg once-daily dose reduced ischemic stroke risk by 26% versus placebo over a median treatment of 14.2 months. The safety picture is where the trade-offs surface: overall major bleeding was similar between groups, but bleeding increased with Sunharbo in patients older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding occurred more commonly. Bayer's own release puts major bleeding at 1.6 versus 1.5 per 100 patient-years and GI bleeding at 2.7 versus 2.1 per 100 patient-years. Bayer reports that stroke is the [fifth](https://www.bayer.com/en-us/united-states/news-and-stories/2026/asundexian-fda?ref=financeherald.com) leading cause of death in the U.S., that about 795,000 Americans have a stroke each year with roughly 87% ischemic, and that about one in five stroke survivors has another stroke within five years, a population the drug is designed to shrink.

### Pricing and the shadow of milvexian

The commercial question sharpens around price and competition. BMO analysts put the monthly list price at $748.50, about [$9,100](https://www.biospace.com/drug-development/bayer-wins-first-in-class-fda-nod-for-blood-thinner-setting-stage-for-bms-j-j-rival?ref=financeherald.com) a year per patient. That is a meaningful sum for a chronic secondary-prevention therapy, and it will face payer scrutiny as Bayer scales U.S. access. Bayer anticipates shipping in mid-to-late November; the drug was approved in China on October 26, 2026 and is under review by the EMA and Japan's MHLW.

The approval also redraws the map for Bayer's rivals. Sunharbo and the older blood thinners work on different clotting pathways: Bayer's Xarelto and Bristol Myers Squibb and Pfizer's Eliquis are Factor Xa inhibitors, while Sunharbo targets Factor XIa, a mechanism long pursued for its potential to prevent clots with less bleeding. Per BMO analysts, the first-in-class clearance derisks the regulatory path for milvexian, the Bristol Myers Squibb and Johnson & Johnson asset positioned as a pipeline replacement ahead of BMS's own patent cliff. Late-stage data for milvexian in secondary stroke prevention is set to read out before the year ends, though other reporting suggests the LIBREXIA-STROKE readout may slip into 2027\. Milvexian is dosed twice daily against Sunharbo's once-daily regimen, a convenience gap Bayer will press in the market.

### One boundary worth watching

There is also a hard limit on the label. Sunharbo is [not](https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk?ref=financeherald.com) approved for stroke prevention in patients with atrial fibrillation, the very indication where asundexian failed in 2023 and the largest commercial pool for any anticoagulant. Bayer's peak-sales case therefore rests on secondary stroke prevention alone, a narrower base than the original €5 billion thesis assumed. The first approval is real, the mechanism is validated, and the floor is rebuilt. Whether the franchise grows from there depends on execution in the U.S. launch, pricing traction, and how quickly a twice-daily rival closes in.